Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo

Gu,Yue; Xiao,Linfeng; Ming,Yanlin; Zheng,Zhizhong; Li,Wengang

doi:10.3892/ijo.2016.3413

Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo

Authors:
- Yue Gu
- Linfeng Xiao
- Yanlin Ming
- Zhizhong Zheng
- Wengang Li
View Affiliations

Affiliations: Medical College of Xiamen University, Xiamen, Fujian, P.R. China, The Research and Development Center for Medicine Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/ijo.2016.3413
Pages: 1868-1876
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Corilagin is a natural plant polyphenol tannic acid with antitumor, anti-inflammatory, and anti-oxidative properties. However, the mechanisms of its actions are largely unknown. Our group reported that corilagin could induce cell inhibition in human breast cancer cell line MCF-7 and human liver hepatocellular carcinoma cell lines HepG2. We report here that corilagin inhibits cholangiocarcinoma (CCA) development through regulating Notch signaling pathway. We found that, in vitro, corilagin inhibited CCA cell proliferation, migration and invasion, promoted CCA cell apoptosis, and inhibited Notch1 and Notch signaling pathway protein expression. Co-immunoprecipitation was used to establish Notch intracellular domain (NICD) interaction with MAML1 and P300 in CCA. Importantly, corilagin reduced Hes1 mRNA level through inhibiting Hes1 promoter activity. In nude mice, corilagin inhibited CCA growth and repressed the expression of Notch1 and mTOR. These results indicate that corilagin may control CCA cell growth by downregulating the expression of Notch1. Therefore, our findings suggest that corilagin may have the potential to become a new therapeutic drug for human CCA.

View Figures

View References

1	Singal AK, Vauthey JN, Grady JJ and Stroehlein JR: Intrahepatic cholangiocarcinoma - frequency and demographic patterns: Thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 137:1071–1078. 2011. View Article : Google Scholar : PubMed/NCBI
2	McGlynn KA, Tarone RE and El-Serag HB: A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 15:1198–1203. 2006. View Article : Google Scholar : PubMed/NCBI
3	Al-Bahrani R, Abuetabh Y, Zeitouni N and Sergi C: Cholangiocarcinoma: Risk factors, environmental influences and oncogenesis. Ann Clin Lab Sci. 43:195–210. 2013.PubMed/NCBI
4	Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
6	Poggi G, Quaretti P, Minoia C, Palumbo I, Villani L, Amatu A, Teragni C, Scelsi M, Zappoli F and Bernardo G: Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: A case report. Anticancer Res. 28:2987–2990. 2008.PubMed/NCBI
7	Shitara K, Ikami I, Munakata M, Muto O and Sakata Y: Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol). 20:241–246. 2008. View Article : Google Scholar
8	Yeo SG, Song JH, Hong EH, Lee BR, Kwon YS, Chang SY, Kim SH, Lee SW, Park JH and Ko HJ: Antiviral effects of Phyllanthus urinaria containing corilagin against human enterovirus 71 and Coxsackievirus A16 in vitro. Arch Pharm Res. 38:193–202. 2015. View Article : Google Scholar
9	Rangkadilok N, Sitthimonchai S, Worasuttayangkurn L, Mahidol C, Ruchirawat M and Satayavivad J: Evaluation of free radical scavenging and antityrosinase activities of standardized longan fruit extract. Food Chem Toxicol. 45:328–336. 2007. View Article : Google Scholar
10	Li N, Luo M, Fu YJ, Zu YG, Wang W, Zhang L, Yao LP, Zhao CJ and Sun Y: Effect of corilagin on membrane permeability of Escherichia coli, Staphylococcus aureus and Candida albicans. Phytother Res. 27:1517–1523. 2013.
11	Chen Y and Chen C: Corilagin prevents tert-butyl hydroperoxide-induced oxidative stress injury in cultured N9 murine microglia cells. Neurochem Int. 59:290–296. 2011. View Article : Google Scholar : PubMed/NCBI
12	Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW, Hau DK, et al: Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. Int Immunopharmacol. 13:308–315. 2012. View Article : Google Scholar : PubMed/NCBI
13	Prasad KN, Yang B, Shi J, Yu C, Zhao M, Xue S and Jiang Y: Enhanced antioxidant and antityrosinase activities of longan fruit pericarp by ultra-high-pressure-assisted extraction. J Pharm Biomed Anal. 51:471–477. 2010. View Article : Google Scholar
14	Wang B: Corilagin nanoparticle-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Acta Pharmacol Sin. 34:14. 2013.
15	Ming Y, Zheng Z, Chen L, Zheng G, Liu S, Yu Y and Tong Q: Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest. Cell Biol Int. 37:1046–1054. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ranganathan P, Weaver KL and Capobianco AJ: Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
17	Takebe N, Harris PJ, Warren RQ and Ivy SP: Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar
18	Miele L, Golde T and Osborne B: Notch signaling in cancer. Curr Mol Med. 6:905–918. 2006. View Article : Google Scholar : PubMed/NCBI
19	Miele L, Miao H and Nickoloff BJ: NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 6:313–323. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhou W, Wang G and Guo S: Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 1836.304–320. 2013.
21	Borggrefe T and Oswald F: The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci. 66:1631–1646. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Guo QY, Zhang XJ, Li X, Li WT, Ma XT and Ma LJ: Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci. 15:9762–9779. 2014. View Article : Google Scholar : PubMed/NCBI
23	Kimpton WG, McKenzie GA, Muller HK, Ruby JC and Poskitt DC: Lymphocyte migration during the development of regional lymph node anergy in experimental tumor growth. Cell Immunol. 75:13–21. 1983. View Article : Google Scholar : PubMed/NCBI
24	Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, Ueda T, Ochiai T and Ochiai A: Extra-tumor perineural invasion predicts postoperative development of peritoneal dissemination in pancreatic ductal adenocarcinoma. Anticancer Res. 21:1407–1412. 2001.PubMed/NCBI
25	El-Habr EA, Levidou G, Trigka EA, Sakalidou J, Piperi C, Chatziandreou I, Spyropoulou A, Soldatos R, Tomara G, Petraki K, et al: Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Arch. 465:473–485. 2014. View Article : Google Scholar : PubMed/NCBI
26	Takebe N, Nguyen D and Yang SX: Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar :
27	Oswald F, Täuber B, Dobner T, Bourteele S, Kostezka U, Adler G, Liptay S and Schmid RM: p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol. 21:7761–7774. 2001. View Article : Google Scholar : PubMed/NCBI
28	Stella MC, Trusolino L, Pennacchietti S and Comoglio PM: Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol. 25:3982–3996. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhao L, Ma Y, Gu F and Fu L: Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer. Chin Med J (Engl). 127:442–447. 2014.
30	Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y and Garcia-Manero G: Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One. 8:e618072013. View Article : Google Scholar : PubMed/NCBI
31	Huppert SS, Jacobsen TL and Muskavitch MA: Feedback regulation is central to Delta-Notch signalling required for Drosophila wing vein morphogenesis. Development. 124:3283–3291. 1997.PubMed/NCBI
32	Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C and Barthélémy P: Angiogenesis and tumor microenvironment: Bevacizumab in the breast cancer model. Target Oncol. 10:189–198. 2015. View Article : Google Scholar
33	Shen B: A new gloden age of natural products drug discovery. Cell. 163:1297–1300. 2015. View Article : Google Scholar : PubMed/NCBI